Induced pluripotent stem cells from a spinal muscular atrophy patient
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy is one of the most common inherited forms of neurological disease leading to infant mortality. Patients have selective loss of lower motor neurons resulting in muscle weakness, paralysis and often death. Although patient fibroblasts have been used extensively to study spinal muscular atrophy, motor neurons have a unique anatomy and physiology which may underlie their vulnerability to the disease process. Here we report the generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy. These cells expanded robustly in culture, maintained the disease genotype and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother. This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease. As such, it represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SMA iPSC-derived motor neurons showed a higher vulnerability with reduced dendritic and axonal length.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Technologies to reprogram adult cells back to a pluripotent state, termed induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Yu et al., 2007), provide an unprecedented platform for studying human genetic disorders (Ebert et al., 2009; Mattis et al., 2015).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Ebert et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“RNA analysis from SMA iPSC-derived motor neuron demonstrates hyperactivation of the endoplasmic reticulum (ER) stress pathway due to activated unfolded SMN [49].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,151
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,451
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Neuronal specification in the spinal cord: inductive signals and transcriptional codes
Jessell, T. M. (2000) · Nature Reviews Genetics · doi:10.1038/35049541 · Cited by 2,089
Cited by
Items 801–900 of 1,000
Induced Pluripotent Stem Cell Modeling of Gaucher’s Disease: What Have We Learned?
Santos, D., & Tiscórnia, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040888 · Cited by 17
“In fact, disease specific iPSc have been successfully derived from patients suffering from a wide range of pathologies [88], including Rett Syndrome [89], Amyotrophic Lateral Sclerosis [90], Spinal Muscular Atrophy [91], Fanconi Anemia [92] and Long Q-T Syndrome [93], among others.”
BackgroundRecent Advances in Therapeutic Applications of Induced Pluripotent Stem Cells
Rami, F., Naderi, S., Mojaver, M., Rahimmanesh, I., Salehi, A. R., & Salehi, R. (2017) · Cellular Reprogramming · doi:10.1089/cell.2016.0034 · Cited by 16
“The relationship between the SMN gene defects and the selective loss of motor neurons was further demonstrated by Chang et al. (2011) who reported that ectopic SMN expression in five SMA iPS cell lines restored normal motor neuron differentiation and rescued the delayed neuritis out-growth.”
InfluentialTransflammation: How Innate Immune Activation and Free Radicals Drive Nuclear Reprogramming
Meng, S., Chanda, P. K., Thandavarayan, R. A., & Cooke, J. P. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7364 · Cited by 18
“These iPSC derivatives may then be used in highthroughput screens for new therapeutic candidates (14, 25, 32, 54, 59, 84, 103, 104, 111, 136).”
BackgroundCurrent Development of iPSC-Based Modeling in Neurodegenerative Diseases
Guo, X., Wang, X., Wang, J., Ma, M., & Ren, Q. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083774 · Cited by 17
“In SMA models, survival motor neuron (SMN) protein levels in motor neurons are reduced, with degenerating neurites and delayed neural differentiation [218–221].”
Bruge, C., Geoffroy, M., Benabidès, M., Pellier, E., Gicquel, E., Dhiab, J., Hoch, L., Richard, I., & Nissan, X. (2022) · Biomedicines · doi:10.3390/biomedicines10061428 · Cited by 14
Liu, L., Yang, J., Otani, Y., Shiga, T., Yamaguchi, A., Oda, Y., Hattori, M., Goto, T., Ishibashi, S., Kawashima, Y., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417186 · Cited by 19
“Numerous studies have shown that disease-specific iPSCs can be differentiated into disease-associated functional cells [17–19].”
BackgroundDeveloping therapies for spinal muscular atrophy
Wertz, M. H., & Şahin, M. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12813 · Cited by 17
Faiz, M., & Nagy, A. (2013) · The Neuroscientist · doi:10.1177/1073858413493148 · Cited by 14
Novosadova, E. V., & Grivennikov, I. A. (2014) · Biochemistry (Moscow) · doi:10.1134/s000629791413001x · Cited by 23
Lie, K. H., Chung, H. C. Y., & Sidhu, K. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-794-1_15 · Cited by 17
Lee, S., & Chung, S. (2016) · Stem Cells International · doi:10.1155/2016/2725670 · Cited by 15
“Fortunately, these disease-related iPSCs were generated without the negative influences of genetic mutations.”
Induced Pluripotent Stem Cell for the Study and Treatment of Sickle Cell Anemia
Reis, L. C. J., Picanço‐Castro, V., Paes, B. C. M. F., Pereira, O. A., Gyuricza, I. G., de Araújo, F. T., Morato-Marques, M., Moreira, L. F., Costa, E. D. B. O., dos Santos, T. P. M., et al. (2017) · Stem Cells International · doi:10.1155/2017/7492914 · Cited by 14
Lin, M. H., Chung, C., Chen, K.-T., Yeh, J., Lee, T., Lee, M., Lee, I., Huang, W.-C., & Yang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010182 · Cited by 14
“The brain-derived neurotrophic factor (BDNF) is a common ingredient for the neural differentiation of iPSCs [26,27], and it additionally is a vital trophic factor in the nervous system that maintains the structure and function of neurons, regulates synaptic transmission, and promotes the axonal regeneration and differ…”
BackgroundGraded and pan-neural disease phenotypes of Rett Syndrome linked with dosage of functional MeCP2
Chen, X., Han, X., Blanchi, B., Guan, W., Ge, W., Yu, Y., & Sun, Y. E. (2020) · Protein & Cell · doi:10.1007/s13238-020-00773-z · Cited by 15
Advances in mt-tRNA Mutation-Caused Mitochondrial Disease Modeling: Patients’ Brain in a Dish
Povea-Cabello, S., Paz, M. V., Suarez-Rivero, J. M., Álvarez-Córdoba, M., Villalón-García, I., Talaverón-Rey, M., Suárez-Carrillo, A., Munuera-Cabeza, M., & Sánchez-Alcázar, J. A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.610764 · Cited by 15
Exploring Motor Neuron Diseases Using iPSC Platforms
Johns, A. E., & Maragakis, N. J. (2022) · Stem Cells · doi:10.1093/stmcls/sxab006 · Cited by 18
Devendran, A. S., Kar, S., Bailey, R. A., & Trivieri, M. G. (2022) · Cells · doi:10.3390/cells11233823 · Cited by 20
Connectivity and circuitry in a dish versus in a brain
Chinchalongporn, V., Koppensteiner, P., Prè, D., Thangnipon, W., Bilo, L., & Arancio, O. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0129-y · Cited by 15
Expert opinion on emerging drugs: chronic low back pain
Hsu, E., Murphy, S., Chang, D. S., & Cohen, S. P. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.993379 · Cited by 15
“1 Stem cell therapy The promising results of feasibility studies using stem cell therapy in treating neurodegenerative conditions such as amyotrophic lateral sclerosis and multiple sclerosis has spurred interest in using stem cell therapy to treat neuropathic pain [187,188].”
BackgroundSchwab, A. J., & Ebert, A. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103112 · Cited by 14
“SMA iPSC-derived motor neurons are significantly reduced after 6 weeks in culture [19,20], but we did not test here whether the addition of SMA iPSC-derived sensory neurons would exacerbate this phenotype.”
BackgroundMethodInfluentialSelf-citationBenevento, M., & Muñoz, J. (2012) · Expert Review of Proteomics · doi:10.1586/epr.12.30 · Cited by 17
Modeling Neurological Disorders by Human Induced Pluripotent Stem Cells
Kunkanjanawan, T., Noisa, P., & Parnpai, R. (2011) · BioMed Research International · doi:10.1155/2011/350131 · Cited by 18
“It is important to note that although some neurons derived from iPSCs predominantly exhibited disease pathology and responded to pharmaceutical agents [31, 34, 35], a number of neural cells from certain diseased iPSCs did not show neuronal pathology, such as Parkinson’s disease [35, 36], Huntington’s disease [37], and…”
BackgroundClinical relevance of stem cell therapies in amyotrophic lateral sclerosis
Srivastava, A. K. (2014) · Neurology India · doi:10.4103/0028-3886.136895 · Cited by 14
Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells
Haque, M. M., Song, J., Fino, K. K., Sandhu, P., Wang, Y., Ni, B., Fang, D., & Song, J. J. (2016) · Cell Transplantation · doi:10.3727/096368916x690467 · Cited by 14
“This approach provides an opportunity to generate patient- or disease-specific PSCs (14,55).”
BackgroundStem Cell-Based Therapies for Polyglutamine Diseases
Mendonça, L. S., Onofre, I., Miranda, C. O., Perfeito, R., Nóbrega, C., & de Almeida, L. P. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-71779-1_21 · Cited by 20
Targeting cell plasticity for regeneration: From in vitro to in vivo reprogramming
Romanazzo, S., Lin, K., Srivastava, P., & Kilian, K. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.007 · Cited by 17
Bioreactor Systems for Tissue Engineering II
Kasper, C., van Griensven, M., & Pörtner, R. (2010) · Springer eBooks · doi:10.1007/978-3-642-16051-6 · Cited by 15
Generation of Histocompatible Androgenetic Embryonic Stem Cells Using Spermatogenic Cells
Zhao, Q., Wang, J., Zhang, Y., Kou, Z., Liu, S., & Gao, S. (2009) · Stem Cells · doi:10.1002/stem.283 · Cited by 14
Li, S., & Li, Q. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.05.025 · Cited by 14
“They further showed that these cells not only maintained the disease genotype, but could also generate motor neurons with selective SMA- related deficits.”
InfluentialTransplantation tolerance in an age of induced pluripotency
Fairchild, P. J. (2009) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32832e9424 · Cited by 15
Potential of Human Induced Pluripotent Stem Cells Derived from Blood and Other Postnatal Cell Types
Ye, Z., & Cheng, L. (2010) · Regenerative Medicine · doi:10.2217/rme.10.38 · Cited by 14
Human stem cells as a model of motoneuron development and diseases
Liu, Y., & Zhang, S. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05537.x · Cited by 14
The gold rush for induced pluripotent stem cells
Webb, S. (2009) · Nature Biotechnology · doi:10.1038/nbt1109-977 · Cited by 18
Connecting Transcriptional Control to Chromosome Structure and Human Disease
Newman, J. J., & Young, R. A. (2010) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2010.75.016 · Cited by 14
“erative medicine and the study of disease mechanisms (Dimos et al. 2008; Ebert et al. 2009; Soldner et al. 2009; Trounson 2009; Kiskinis and Eggan 2010).”
BackgroundBioreactors for Stem Cell Expansion and Differentiation
Gonçalves, A. I., Berdecka, D., Rodrigues, M. T., Reis, R. L., & Gomes, M. E. (2018) · CRC Press eBooks · doi:10.1201/9780429453144 · Cited by 15
Systematic approaches to dissect biological processes in stem cells by image‐based screening
Erdmann, G., Volz, C., & Boutros, M. (2012) · Biotechnology Journal · doi:10.1002/biot.201200117 · Cited by 14
“Examples are iPS cell-derived cardiomyocytes with longQT syndrome [15], reprogrammed cells from Huntington and Parkinson patients [16] and iPS cells derived from patients with spinal muscular atrophy [17], which maintained disease specific phenotypes after differentiation.”
BackgroundImplications and limitations of cellular reprogramming for psychiatric drug development
Tobe, B. T. D., Brandel, M. G., Nye, J. S., & Snyder, E. Y. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.124 · Cited by 9
Rim, J. S., Strickler, K. L., Barnes, C. W., Harkins, L. L., Staszkiewicz, J., Gimble, J. M., Leno, G. H., & Eilertsen, K. J. (2012) · Stem Cell Discovery · doi:10.4236/scd.2012.22008 · Cited by 14
“Indeed, several reports have described and validated “disease-in-a-dish” model systems [4-8].”
Kubota, T., Miyake, K., Hirasawa, T., Nagai, K., & Koide, T. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09r20fm · Cited by 14
Induced human pluripotent stem cells and advanced therapies
Liras, A. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.01.010 · Cited by 17
Human pluripotent stem cells on artificial microenvironments: a high content perspective
Viswanathan, P., Gaskell, T. L., Moens, N., Culley, O. J., Hansen, D. M., Gervasio, M. K. R., Yeap, Y. J., & Danovi, D. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00150 · Cited by 14
Abdelli, L. S., Merino, H., Rocher, C., & Singla, D. K. (2012) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y11-130 · Cited by 15
Modelling multiple sclerosis using induced pluripotent stem cells
Martínez-Larrosa, J., Matute‐Blanch, C., Montalbán, X., & Comabella, M. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577425 · Cited by 16
Disease modeling and stem cell immunoengineering in regenerative medicine using CRISPR/Cas9 systems
Antao, A. M., Karapurkar, J. K., Lee, D. R., Kim, K.-S., & Ramakrishna, S. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.11.026 · Cited by 14
Induced pluripotent stem cells for modeling of pediatric neurological disorders
Jang, J., Quan, Z., Yum, Y. J., Song, H. S., Paek, S., & Kang, H. (2014) · Biotechnology Journal · doi:10.1002/biot.201400010 · Cited by 16
“[67] reported about generating iPSCs from skin fibroblast samples taken from a child with SMA.”
BackgroundSendtner, M. (2009) · Nature · doi:10.1038/457269a · Cited by 13
An Examination of Regenerative Medicine-Based Strategies for the Urinary Bladder
Sharma, A. K. (2011) · Regenerative Medicine · doi:10.2217/rme.11.47 · Cited by 14
Important advances in Alzheimer’s disease from the use of induced pluripotent stem cells
Majolo, F., Marinowic, D. R., Machado, D. C., & da Costa, J. C. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0501-5 · Cited by 17
Induced Pluripotent Stem Cells: Hope in the Treatment of Diseases, including Muscular Dystrophies
Beghini, D. G., Horita, S. I. M., Cascabulho, C. M., Alves, L. A., & Henriques‐Pons, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155467 · Cited by 24
“spinal muscular atrophy motor neurons [48]”
Acyclic retinoid induces differentiation and apoptosis of murine hepatic stem cells
Guan, H.-B., Nie, Y., Zheng, Y., Takiguchi, K., Yu, H., Zhang, R., Li, B., Tsuchida, T., & Taniguchi, H. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0046-9 · Cited by 14
“Recent studies suggest that retinoic acid can work in a paracrine manner to control the differentiation of pluripotent cells [8,9].”
BackgroundÁvila-Robinson, A., & Sengoku, S. (2017) · Scientometrics · doi:10.1007/s11192-017-2436-5 · Cited by 19
Traldi, C., Chiappini, V., Menduti, G., Tonda-Turo, C., & Boido, M. (2023) · Frontiers in Medical Engineering · doi:10.3389/fmede.2023.1270943 · Cited by 7
“Indeed, maintaining the patient genetic background ensures the in vitro reproduction of different mutations of numerous diseases: the fi rst successful in vitro model of a genetically inherited disease was on spinal muscular atrophy in 2008 (Ebert et al., 2009).”
Thiry, L., Sirois, J., Durcan, T. M., & Stifani, S. (2024) · Communications Biology · doi:10.1038/s42003-024-05925-z · Cited by 16
OrganDots – an organotypic 3D tissue culture platform for drug development
Sundström, L., Biggs, T. E., Laskowski, A., & Stoppini, L. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.686488 · Cited by 14
“For example, these may prove particularly useful where it is generally not possible to easily obtain biopsy material as in efficacy studies for neurological conditions [49-51] or for profiling drug responses in cardiac safety studies based on genetic risk profiles [52,53].”
BackgroundStem cells: disease models that show and tell
Marx, V. (2015) · Nature Methods · doi:10.1038/nmeth.3263 · Cited by 12
Epigenetics of cell fate reprogramming and its implications for neurological disorders modelling
Grzybek, M., Golonko, A., Walczak, M., & Lisowski, P. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.11.007 · Cited by 14
Cellular Reprogramming: A New Technology Frontier in Pharmaceutical Research
Brock, A., Goh, H.-T., Yang, B., Lu, Y., Li, H., & Loh, Y. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0618-z · Cited by 13
“as previously mentioned, hiPSCs models successfully recapitulated the phenotype of spinal muscular atrophy (71), familial dysautonomia (72), Rett syndrome (73) and long QT syndrome (74,75), with the reversal of phenotypes observed by application of known drugs.”
Swelstad, B. B., & Kerr, C. L. (2009) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s8051 · Cited by 15
Functional genomics of the brain: uncovering networks in the CNS using a systems approach
Konopka, G. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.139 · Cited by 13
Nissan, X., Blondel, S., & Peschanski, M. (2011) · Biochemical Society Transactions · doi:10.1042/bst20110659 · Cited by 13
Mishima, T., Fujioka, S., Fukae, J., Yuasa‐Kawada, J., & Tsuboi, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123870 · Cited by 13
“Importantly, the patient iPSC-derived neurons exhibited disease-related phenotypes and responsiveness to treatment, with drugs such as valproic acid, demonstrating that human iPSCs can be used for modeling of inherited diseases [27].”
BackgroundSomatic cell reprogramming as a tool for neurodegenerative diseases
Ebrahımı, A., Keske, E., Mehdipour, A., Kalan, A. E., & Ghorbani, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108663 · Cited by 14
Induced Pluripotent Stem Cells: Progress and Future Perspectives in the Stem Cell World
Rezanejad, H., & Matin, M. M. (2012) · Cellular Reprogramming · doi:10.1089/cell.2012.0039 · Cited by 13
“So far, many disease-specific iPSCs have been generated (Dimos et al., 2008; Ebert et al., 2009; Hanna et al., 2007; Lee et al., 2009; Ma et al., 2012; Raya et al., 2009; Yi et al., 2012).”
Establishment of a Molecular Diagnostic System for Spinal Muscular Atrophy
Zeng, J., Lin, Y., Yan, A.-Z., Ke, L., Zhu, Z., & Lan, F. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.009 · Cited by 12
How to cross immunogenetic hurdles to human embryonic stem cell transplantation
de Rham, C., & Villard, J. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0262-z · Cited by 14
“This occurred in patients with spinal muscular atrophy [37], and iPS generated from fibroblasts of a sick child proliferated in culture while maintaining the genotype of the disease.”
BackgroundThe protective effects of beta-lactam antibiotics in motor neuron disorders
Hedlund, E. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.002 · Cited by 13
Bosnali, M., Münst, B., Thier, M. C., & Edenhofer, F. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0095-2 · Cited by 16
“Nanog also appears to play a role in the reprogramming process of human somatic cells [96–98].”
BackgroundFeeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells
Callahan, S. J., Mica, Y., & Studer, L. (2016) · Journal of Visualized Experiments · doi:10.3791/53806 · Cited by 15
Brownstone, R. M., & Stuart, D. G. (2011) · Brain Research · doi:10.1016/j.brainres.2011.06.008 · Cited by 14
iPS cell technology gains momentum in drug discovery
Webb, S. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2867 · Cited by 12
Signoria, I., Zwartkruis, M. M., Geerlofs, L., Perenthaler, E., Faller, K. M. E., James, R., McHale-Owen, H., Green, J. W., Kortooms, J. V., Snellen, S. H., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101379 · Cited by 12
“We obtained additional written and oral informed consent for skin biopsies from each adult patient and from both parents of each participating minor.”
Embryonic and induced pluripotent stem cell differentiation as a tool in neurobiology
Nikoletopoulou, V., & Tavernarakis, N. (2012) · Biotechnology Journal · doi:10.1002/biot.201200040 · Cited by 13
“iPS cells were derived from a child with a mutation in SMN (SMA type 1) and from his unaffected mother as a control [112].”
BackgroundCurrent status of human pluripotent stem cell based in vitro toxicity tests
Klarić, M., Winkler, J., Vojnits, K., Meganathan, K., Jagtap, S., Enseñat‐Waser, R., Hescheler, J., Sachinidis, A., & Bremer‐Hoffmann, S. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s361 · Cited by 13
“who generated iPSCs from a patient with spinal muscular atrophy and differentiated them towards motoneurons (18).”
BackgroundLoya, K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00011-6 · Cited by 16
Wang, Q., Lu, J., Fan, K., Xu, Y., Xiong, Y., Sun, Z., Zhai, M., Zhang, Z., Zhang, S., Song, Y. L., et al. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2100701 · Cited by 11
“, 2009; Ichimura and Shiba, 2017) make them a promising and logical choice for model‐ ling monogenic diseases and compound screening (Ebert et al., 2009; Shi et al., 2017).”
BackgroundTan, Y., Lu, T., Chen, Y. G., Witman, N., Yan, B., Li, Y., Liu, M., Gong, Y., Ai, X., Luo, R., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10522 · Cited by 11
Induced Pluripotent Stem Cells in Cardiovascular Research
Sinnecker, D., Dirschinger, R. J., Goedel, A., Moretti, A., Lipp, P., & Laugwitz, K. (2012) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2012_6 · Cited by 13
Modeling complex neuropsychiatric disorders with human induced pluripotent stem cells
Tobe, B. T. D., Snyder, E. Y., & Nye, J. S. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.05.007 · Cited by 12
Genetic Basis of Inherited Macular Dystrophies and Implications for Stem Cell Therapy
Mellough, C., STEEL, D. H., & Lako, M. (2009) · Stem Cells · doi:10.1002/stem.159 · Cited by 14
Modeling complex neuropsychiatric disease with induced pluripotent stem cells
Ross, P. J., & Ellis, J. (2010) · F1000 Biology Reports · doi:10.3410/b2-84 · Cited by 12
“For example, one report showed that treatment of iPSC-derived motor neurons from patients with spinal muscular atrophy with valproic acid or tobramycin increased expression of the hemizygousmutated gene that causes the disease [27].”
BackgroundInduced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
Sánchez‐Danés, A., Benzoni, P., Memo, M., Dell`Era, P., Raya, Á., & Consiglio, A. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152731131200128 · Cited by 12
Quo vadis motor neuron disease?
Balendra, R., & Patani, R. (2016) · World Journal of Methodology · doi:10.5662/wjm.v6.i1.56 · Cited by 12
Tian, Z., Guo, F., Biswas, S., & Deng, W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040594 · Cited by 12
“Patient- and disease-specific induced pluripotent stem cells (iPSCs) have been established via viral- or nanocarrier-based method for a number of diseases, such as multiple sclerosis [5], Alzheimer’s disease [6], amyotrophic lateral sclerosis [7], spinal muscular atrophy [8], as well as Down syndrome, Parkinson diseas…”
Dai, S., Li, R., Long, Y., Titus, S., Zhao, J., Huang, R., Xia, M., & Zheng, W. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116670068 · Cited by 12
Studying Kidney Disease Using Tissue and Genome Engineering in Human Pluripotent Stem Cells
Garreta, E., Gonzãlez, F., & Montserrat, N. (2017) · The Nephron journals/Nephron journals · doi:10.1159/000480710 · Cited by 13
Investigating pediatric disorders with induced pluripotent stem cells
Durbin, M. D., Cadar, A. G., Chun, Y. W., & Hong, C. C. (2018) · Pediatric Research · doi:10.1038/s41390-018-0064-2 · Cited by 12
Patient-Derived Stem Cell Models in SPAST HSP: Disease Modelling and Drug Discovery
Wali, G., Sue, C. M., & Mackay‐Sim, A. (2018) · Brain Sciences · doi:10.3390/brainsci8080142 · Cited by 15
“Patient-derived iPS cells have been used for disease modelling of numerous neurological disorders, including Parkinson’s disease [42], Amyotrophic lateral sclerosis [43], Spinal muscular atrophy [44], and Alzheimer’s disease [45], and they have been used to screen for drugs [46].”
BackgroundMotor Neuron Generation from iPSCs from Identical Twins Discordant for Amyotrophic Lateral Sclerosis
Seminary, E. R., Santarriaga, S., Wheeler, L., Mejaki, M., Abrudan, J., Demos, W., Zimmermann, M. T., Urrutia, R. A., Fee, D. B., Barkhaus, P. E., et al. (2020) · Cells · doi:10.3390/cells9030571 · Cited by 12
“Pluripotency was confirmed through qPCR for Oct4, Sox2, and Nanog; immunocytochemistry for Oct4, Sox2, Tra 1-81; and embryoid body (EB) formation and subsequent immunocytochemistry for α-fetoprotein (endoderm), smooth muscle actin (mesoderm), and Tuj1 (ectoderm), as described previously [15,16].”
MethodSelf-citationBroccoli, V., Rubio, A., Taverna, S., & Yekhlef, L. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215577585 · Cited by 14
“Due to its therapeutic implications, different groups have worked to develop a method to obtain motor neurons based on the synergic action of SHH and RA treatments.(3,4,7,8,18) The major limitation shared by these protocols is that they are very laborious and highly time-consuming.”
MethodStrategies for future histocompatible stem cell therapy
Nehlin, J. O., & Barington, T. (2009) · Biogerontology · doi:10.1007/s10522-009-9213-7 · Cited by 11
“Primary dermal fibroblasts from an 82-year-old patient suffering from amyotrophic lateral sclerosis (ALS) (Dimos et al. 2008) or from a child with spinal muscular atrophy (SMA) (Ebert et al. 2009) were reprogrammed to iPS cells, and directed in vitro to differentiate into motor neurons, the cell types that are lost in…”
BackgroundInduced Pluripotent Stem Cells: The Dragon Awakens
Han, W., Zhao, Y., & Fu, X. (2010) · BioScience · doi:10.1525/bio.2010.60.4.6 · Cited by 12
“Researchers recently established various iPSCs from patients with inherited diseases and were able to use them to successfully model a specific pathology (Dimos et al. 2008, Park et al. 2008b, Ebert et al. 2009).”
BackgroundZeb, H., Khan, I. N., Munir, I., Ramadan, W. S., Ahmad, M., Hussein, D. M., Kamal, M. A., & Alkarim, S. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666161004145709 · Cited by 11
Genome editing in animals: an overview
Bharati, J., Punetha, M., Kumar, B. A. A. S., Vidyalakshmi, G. M., Sarkar, M., D’Occhio, M. J., & Singh, R. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816352-8.00003-5 · Cited by 13
Microfluidic systems for controlling stem cell microenvironments
Selimović, Š., Kaji, H., Bae, H., & Khademhosseini, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813671-3.00002-5 · Cited by 13
Stem Cell Biology in Health and Disease
Dittmar, T., & Zänker, K. S. (2009) · Springer eBooks · doi:10.1007/978-90-481-3040-5 · Cited by 12
Tariq, F. A., Holčík, M., & MacKenzie, A. (2013) · InTech eBooks · doi:10.5772/53800 · Cited by 24
NeuroLINCS Proteomics: Defining human-derived iPSC proteomes and protein signatures of pluripotency
Matlock, A. D., Vaibhav, V., Holewinski, R. J., Venkatraman, V., Dardov, V. J., Manalo, D.-M., Shelley, B., Ornelas, L., Bañuelos, M. G., Mandefro, B., et al. (2023) · Scientific Data · doi:10.1038/s41597-022-01687-7 · Cited by 11
Self-citationCRISPRi: a way to integrate iPSC-derived neuronal models
Franks, S. N. J., Heon‐Roberts, R., & Ryan, B. J. (2024) · Biochemical Society Transactions · doi:10.1042/bst20230190 · Cited by 13
Pluripotent Stem Cell-Derived Pancreatic β-Cells: Potential for Regenerative Medicine in Diabetes
Kao, D.-I., & Chen, S. (2012) · Regenerative Medicine · doi:10.2217/rme.12.27 · Cited by 10
Wang, L., Nguyen, T. M., Rosa‐Garrido, M., Zhou, Y., Cleveland, D. C., & Zhang, J. J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1108340 · Cited by 11
“The scarcity of CMs for therapeutic applications, as well as mechanistic studies and drug testing, was alleviated by the development of induced pluripotent stem cells (iPSCs), (Takahashi and Yamanaka, 2006), which are reprogrammed from cells of somatic tissues and, like embryonic stem cells (ESCs), can self-replicate…”
Background
Metadata
- Authors
- Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Missouri (US)
- Corresponding author
- Ebert, Allison D.
- Svendsen, Clive N.
- Venue
- Nature
- Published
- 2008-12-21
- Volume
- 457
- Issue
- 7227
- Pages
- 277-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2659408
- OpenAlex
- W2145492799
- Cited by
- 1,441
- References
- 42
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 28 · 2023: 31 · 2022: 36 · 2021: 33 · 2020: 46 · 2019: 54 · 2018: 53 · 2017: 60 · 2016: 85 · 2015: 109 · 2014: 112 · 2013: 145 · 2012: 199
- FWCI
- 58.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (T32AG027566)
- National Institute of General Medical Sciences (T32GM008396)
- National Institute of Neurological Disorders and Stroke (R01 NS41584, P01NS057778, R01NS041584)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD054413)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, motor neurons, SMN1, SMN2, dermal fibroblasts, disease modeling, neural progenitor cells, drug screening, inherited neurological diseases, Huntington's disease
- MeSH terms
- Cell Differentiation, Cell Separation, Cells, Cultured, Child, Female, Fibroblasts, Gene Expression Regulation, Humans, Male, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Cell Lineage, Pluripotent Stem Cells, Survival of Motor Neuron 1 Protein, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.